Related Experiment Videos
[Scleromyxedema associated with myopathy]
J Catalá1, J López-Aldeguer, J J Vílchez
1Servicio de Neurología, Hospital La Fe, Valencia.
Revista Clinica Espanola
|July 1, 1993
Summary
Scleromyxedema, a skin condition, can cause systemic issues like myopathy (muscle disease). Treatment with corticosteroids and cyclophosphamide resolved muscle symptoms, suggesting scleromyxedema is a systemic disease.
Area of Science:
- Dermatology
- Neurology
- Rheumatology
Background:
- Scleromyxedema is a rare connective tissue disease characterized by skin thickening.
- Systemic involvement is increasingly recognized in scleromyxedema.
- Myopathy is a potential systemic manifestation.
Observation:
- A 45-year-old male presented with scleromyxedema and progressive muscular weakness.
- The muscle weakness, predominantly proximal, led to functional incapacity after 6 years of dermatologic symptoms.
- Muscle biopsy initially showed abnormalities consistent with myopathy.
Findings:
- Treatment with corticosteroids and cyclophosphamide led to the resolution of muscular symptomatology.
- A follow-up muscle biopsy after treatment was normal.
- The patient's response to therapy highlights the treatable nature of myopathy in this context.
Implications:
- The frequent association of scleromyxedema with myopathy and other systemic findings supports its classification as a systemic disease.
- Recognizing scleromyxedema as a systemic disorder is crucial for comprehensive patient management.
- Further research into the systemic manifestations of scleromyxedema is warranted.